280 related articles for article (PubMed ID: 33275150)
41. A Targeted Approach for Congenital Cytomegalovirus Screening Within Newborn Hearing Screening.
Fowler KB; McCollister FP; Sabo DL; Shoup AG; Owen KE; Woodruff JL; Cox E; Mohamed LS; Choo DI; Boppana SB;
Pediatrics; 2017 Feb; 139(2):. PubMed ID: 28049114
[TBL] [Abstract][Full Text] [Related]
42. Newborn screening for congenital cytomegalovirus using real-time polymerase chain reaction in umbilical cord blood.
Barkai G; Barzilai A; Mendelson E; Tepperberg-Oikawa M; Roth DA; Kuint J
Isr Med Assoc J; 2013 Jun; 15(6):279-83. PubMed ID: 23882891
[TBL] [Abstract][Full Text] [Related]
43. Recognition, treatment, and sequelae of congenital cytomegalovirus in Australia: An observational study.
Bartlett AW; Hall BM; Palasanthiran P; McMullan B; Shand AW; Rawlinson WD
J Clin Virol; 2018 Nov; 108():121-125. PubMed ID: 30300787
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.
Hamers FF; Rumeau-Pichon C
BMC Pediatr; 2012 Jun; 12():60. PubMed ID: 22681855
[TBL] [Abstract][Full Text] [Related]
45. Congenital cytomegalovirus infection.
Fowler KB; Boppana SB
Semin Perinatol; 2018 Apr; 42(3):149-154. PubMed ID: 29503048
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model.
Tang J; Liang Y; O'Neill C; Kee F; Jiang J; Congdon N
Lancet Glob Health; 2019 Jul; 7(7):e968-e978. PubMed ID: 31122906
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
[TBL] [Abstract][Full Text] [Related]
48. Screening of the hearing of newborns - Update.
Schnell-Inderst P; Kunze S; Hessel F; Grill E; Siebert U; Nickisch A; von Voß H; Wasem J
GMS Health Technol Assess; 2006 Nov; 2():Doc20. PubMed ID: 21289971
[TBL] [Abstract][Full Text] [Related]
49. Neonatal hearing screening: modelling cost and effectiveness of hospital- and community-based screening.
Grill E; Uus K; Hessel F; Davies L; Taylor RS; Wasem J; Bamford J
BMC Health Serv Res; 2006 Feb; 6():14. PubMed ID: 16504089
[TBL] [Abstract][Full Text] [Related]
50. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.
Luan FL; Kommareddi M; Ojo AO
Transplantation; 2011 Jan; 91(2):237-44. PubMed ID: 21169881
[TBL] [Abstract][Full Text] [Related]
51. Universal neonatal cytomegalovirus screening using saliva - report of clinical experience.
Barkai G; Ari-Even Roth D; Barzilai A; Tepperberg-Oikawa M; Mendelson E; Hildesheimer M; Kuint J
J Clin Virol; 2014 Aug; 60(4):361-6. PubMed ID: 24881490
[TBL] [Abstract][Full Text] [Related]
52. Decision tree-Markov model of perinatal depression screening: a cost-utility analysis.
Yang Y; Zheng R; Yang L; Huang X; Zhang T
Front Public Health; 2024; 12():1308867. PubMed ID: 38832225
[TBL] [Abstract][Full Text] [Related]
53. Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis.
Grill E; Hessel F; Siebert U; Schnell-Inderst P; Kunze S; Nickisch A; Wasem J
BMC Public Health; 2005 Jan; 5():12. PubMed ID: 15679901
[TBL] [Abstract][Full Text] [Related]
54. Ethical and Public Health Implications of Targeted Screening for Congenital Cytomegalovirus.
Gievers LL; Holmes AV; Loyal J; Larson IA; Oliveira CR; Waldman EH; Khaki S
Pediatrics; 2020 Jul; 146(1):. PubMed ID: 32591436
[TBL] [Abstract][Full Text] [Related]
55. Health Care Resource Utilization and Economic Burden Associated With Congenital Cytomegalovirus Infection: A Longitudinal Analysis of Data From Clinical Practice at a Large Health Care Provider in Israel.
Weil C; Wang WV; Marks MA; Bilavsky E; Sinha A; Chodick G; Goodman E
Clin Ther; 2022 Feb; 44(2):282-294. PubMed ID: 35115189
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France.
N'Diaye DS; Launay O; Picone O; Tsatsaris V; Azria E; Rozenberg F; Schwarzinger M; Yazdanpanah Y
Vaccine; 2018 Feb; 36(10):1285-1296. PubMed ID: 29397227
[TBL] [Abstract][Full Text] [Related]
57. Congenital CMV infection: prevalence in newborns and the impact on hearing deficit.
Engman ML; Malm G; Engstrom L; Petersson K; Karltorp E; Tear Fahnehjelm K; Uhlen I; Guthenberg C; Lewensohn-Fuchs I
Scand J Infect Dis; 2008; 40(11-12):935-42. PubMed ID: 18720260
[TBL] [Abstract][Full Text] [Related]
58. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
59. Contribution of targeted saliva screening for congenital CMV-related hearing loss in newborns who fail hearing screening.
Ari-Even Roth D; Lubin D; Kuint J; Teperberg-Oikawa M; Mendelson E; Strauss T; Barkai G
Arch Dis Child Fetal Neonatal Ed; 2017 Nov; 102(6):F519-F524. PubMed ID: 28468898
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus.
Dempsey AF; Pangborn HM; Prosser LA
Vaccine; 2012 Jun; 30(27):4060-6. PubMed ID: 22525796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
